Welcome to our dedicated page for Illumina news (Ticker: ILMN), a resource for investors and traders seeking the latest updates and insights on Illumina stock.
Illumina Inc (ILMN), a global leader in genomic sequencing technologies, provides critical tools advancing precision medicine and life science research. This dedicated news hub offers investors and industry professionals centralized access to official press releases, financial disclosures, and strategic updates directly from the company.
Track developments across key areas including quarterly earnings, sequencing platform innovations, and global health partnerships. Stay informed about regulatory milestones, product launches, and collaborations shaping the future of genomic analysis. Bookmark this page for unfiltered access to Illumina's latest announcements, enabling data-driven decisions in the rapidly evolving biotechnology sector.
Illumina reported Q1 2022 revenue of $1.22 billion, a 12% increase year-over-year. However, diluted EPS fell to $0.55 from $1.00 in Q1 2021. Despite these results, the company reaffirms its 2022 revenue growth guidance of 14-16% and expects diluted EPS of $2.33 to $2.53. GRAIL, acquired in 2021, showed promising partnerships but reported an operating loss of $172 million. Illumina continues to advance in oncology and genetic testing, with cash reserves at $1.4 billion.
Illumina (NASDAQ: ILMN) and Deerfield Management have announced a five-year partnership aimed at revolutionizing drug discovery through a genetics-led approach. This collaboration seeks to enhance the identification of therapeutic targets and expedite the development of novel therapies for unmet medical needs. Leveraging genomic tools and artificial intelligence, the partnership aims to reduce the high costs and long timelines associated with drug development, fostering more efficient paths to market for potentially life-saving treatments.
Illumina, Inc. (NASDAQ: ILMN) will participate in the BofA Securities 2022 Healthcare Conference on May 12, 2022. The fireside chat will take place at 12:00pm PT (3:00pm ET). Investors can access the live webcast on Illumina's website in the Investor Info section. A replay will be available for 30 days post-event. Illumina focuses on DNA sequencing and array-based technologies, enhancing human health through genomic insights across several sectors including oncology and agriculture.
Illumina (NASDAQ: ILMN) announced a collaboration with Hannover Medical School to enhance genetic disorder diagnosis using whole-genome sequencing (WGS) for critically ill children. The study will involve at least 100 patients and aims to demonstrate the efficacy of rapid WGS in providing timely diagnoses and treatment. This initiative intends to reshape eligibility criteria for WGS in German healthcare, amid growing global evidence of its clinical value. Illumina will supply necessary reagents, highlighting the significant impact of WGS in pediatric precision medicine.
The PGA TOUR Champions has partnered with GRAIL to host the inaugural Galleri Classic from March 20-26, 2023, at the historic Mission Hills Country Club in Rancho Mirage, California. The tournament will feature 78 professionals competing for a total purse of $2.2 million. This marks the first PGA TOUR Champions event in Coachella Valley since 1993 and aims to raise awareness for multi-cancer early detection. GRAIL, a subsidiary of Illumina (ILMN), focuses on early cancer detection technologies.
Illumina, Inc. (NASDAQ: ILMN) will release its first quarter 2022 financial results on May 5, 2022, after market close. CEO Francis deSouza and CFO Sam Samad will host a conference call at 2:00 PM PT to discuss the results. Interested parties can access the call via Illumina's website or by phone. A replay will be available online for at least 30 days. This announcement highlights Illumina's ongoing commitment to transparency and investor communication.
Illumina has launched a new Solution Center in São Paulo, Brazil, aimed at boosting access to next-generation sequencing training and expertise. This facility underscores Illumina's commitment to expanding genomic access in Latin America amid growing demand for clinical genomics. The 11,000 square-foot center features advanced technology and will host training sessions to optimize user experience. Illumina's long-term engagement in Brazil, including a partnership to track COVID-19, positions it well within the local healthcare market.
Illumina, a leader in DNA sequencing, appointed John Frank as Chief Public Affairs Officer, effective April 18. Frank joins from Microsoft, where he spent 20 years in government affairs. In his new role, he will oversee global government affairs, public policy, patient advocacy, and Corporate Social Responsibility. Frank will advise Illumina's leadership on geopolitical and policy matters affecting the company, aiming to enhance patient access to genomics globally. CEO Francis deSouza emphasized the importance of Frank's expertise in driving impactful change in healthcare.
Illumina (NASDAQ: ILMN) released its 2021 Corporate Social Responsibility (CSR) Report, emphasizing its commitment to environmental, social, and governance (ESG) principles. Key highlights include achieving coverage of 1 billion lives for genomic testing, a commitment to net zero emissions by 2050, and sourcing 59% of global electricity from renewable sources. The company also contributed over $14.5 million to charity, maintained a zero net pay gap, and increased female representation in leadership by 5%. These efforts underline Illumina's role in advancing health equity and sustainability.
Illumina, Inc. (NASDAQ: ILMN) announced the investment in seven new genomics startups as part of its fourth global funding cycle for Illumina Accelerator. This brings the portfolio to 68 startups, with 93% of graduates successfully securing additional capital. The new startups focus on diverse areas like therapeutics, diagnostics, and sustainable foods. Applications for the next funding cycle are due by April 1, 2022. Illumina Accelerator offers seed investments, access to advanced tools, and business guidance to help entrepreneurs drive innovation in genomic medicine.